Dr. Ghania Chikh: Expertise, Experience and Engagement with the Team!
The Acuitas team consists of brilliant, talented and experienced scientists and business professionals who are also interesting, engaging and fun-loving. This is just one of the many things that makes us unique at Acuitas. For Acuitas, the word “team” isn’t based
Acuitas Is a Great Place to Work! (Why You Should Work Here!)
Finding a great place to work which is purpose driven is a goal for many, and we completely understand (and endorse!) that. Good work/life integration is an important aspect of our professional lives – and so is working with a
Our Unique Business Model
The Acuitas business model is unique. As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, our full focus is on refining and improving our LNP for use by our partners. Supporting partner success is at the heart
Acuitas – Who We Are and How We Got Here
As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, the Acuitas team advances human health through our work with our partners – and by continuing to refine and improve our LNP. We are growing our team and
Acuitas Scientists Co-Author Nature Article
Acuitas Therapeutics’ Chief Scientific Officer, Dr. Ying Tam, and Director of Formulation Development, Paulo Lin, co-authored (with several other scientists) a study titled “Molecular fate-mapping of serum antibody responses to repeat immunization” that was recently published in Nature. Please click
Acuitas Therapeutics Video Update
Acuitas Therapeutics is the global leader in the field of lipid nanotechnology. We specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). We work with partners to develop new therapies to address unmet
An Interview with Dr. Thomas Madden, Ph.D.
Acuitas Therapeutics President & CEO, Dr. Thomas Madden, was recently interviewed about the work we do, our proprietary lipid nanoparticle delivery system, and how we support partners worldwide in the development of COVID-19 vaccines. It’s a great overview of who
mRNA Vaccines
We’ve been receiving positive feedback on our blog posts. In fact, a teacher friend of one of our team members said that some of our information helped her to map out some course work that focused on vaccines, especially around
mRNA-LNP COVID-19 Vaccines
When asked about the work we do at Acuitas Therapeutics by those who aren’t in our field, it can be a little challenging to explain. We specialize in the development of lipid nanoparticle delivery systems for molecular therapeutics, which sounds
A Little About Us…
As we work to increase engagement with our stakeholders and members of the public who are interested in the work that we do, we thought it would be a good idea to share a little about us. Acuitas Therapeutics is